TABLE 2.
In vitro and in vivo correlation for fluconazole in severe Candida infections
| Outcome | No. of cases
|
|||
|---|---|---|---|---|
| Susceptiblea | Dose-dependent susceptibleb | Resistantc | Total | |
| Clinical cure | 19 | 4 | 0 | 23 |
| Clinical failure | 5 | 2 | 2 | 9 |
| Total | 24 | 6 | 2 | 32 |
a
Fluconazole 48-h MIC, ≤8 μg/ml (candidemia [14] success/failure, 11/3; peritonitis [4], 3/1; pyelonephritis [3], 3/0; pyothorax [1], 1/0; pneumonia [1], 1/0; infective endocarditis [1], 0/1).
b
Fluconazole 48-h MIC, 16 to 32 μg/ml (candidemia [5] success/failure, 3/2; pyelonephritis [1], 1/0).
c
Fluconazole 48-h MIC, ≥64 μg/ml (candidemia [2] success/failure, 0/2).